Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
The U.S. is the last major regulatory hurdle before Bayer AG’s merger with Monsanto Co. can close after the parties reached a deal with the Russian Federal Antitrust Service (FAS).
Bloomberg reported that Bayer worked out a deal with the Russian regulator April 20 to transfer certain assets to Russia. FAS had delayed approving the transaction until the merged company agreed to share technology and data with the country. It’s the first time Russian authorities have demanded corporate secrets in exchange for access to the local market.
The approval brings Bayer a step closer to closing its purchase of Monsanto. A Bayer spokesman told Bloomberg Law that the deal is on target to close in the second half of 2018.
The deal has already been pending for 19 months. The parties announced the merger in September 2016. Shareholders cleared the deal relatively quickly, but as global companies, Bayer and Monsanto needed regulatory clearance in a broad swath of jurisdictions.
Those approvals have been slow for a number of reasons. The scope of the merger and the high concentration in the agrochemical industry, dictated a lengthy and complex review. In smaller jurisdictions with fewer resources, the size of the merger and importance of the agricultural sector posed a challenge.
Besides the Russian clearance, the deal has garnered some important regulatory approvals. China conditionally approved the deal on March 13, and the EU cleared the merger conditioned on substantial divestitures on March 21. Brazil conditionally approved the deal in February.
India, where the merger is still waiting on clearance, presents a more complex problem. The Delhi High Court last week dealt Monsanto a blow in ruling its genetically modified cotton seed is not eligible for Indian patent protection.
A Monsanto spokeswoman told Bloomberg Law that the company will appeal the ruling to India’s Supreme Court upon receipt of the lower court’s order. But the ruling, for now, casts more concern on Monsanto’s Indian operations, and modern agrochemical more generally in the country, than the slow merger approval.
To contact the reporter on this story: Eleanor Tyler in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Fawn Johnson at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)